文献速递神经创伤神经重症

抗血小板与抗凝药物使用对重症监护室治疗创伤性脑损伤患者损伤严重程度及死亡率的影响

Effect of antiplatelet and anticoagulant medication use on injury severity and mortality in patients with traumatic brain injury treated in the intensive care unit.
PubMed 文献 · Acta Neurochir (Wien) · 2023-11-01

基于芬兰重症监护联盟数据库的回顾性多中心观察研究,纳入2003至2013年四所大学医院ICU收治的3031例成人TBI患者,随访至2016年底。抗血小板药(OR 1.62,95%CI 1.02-2.58)与抗凝药(OR 1.43,95%CI 1.06-1.94)均与1年死亡率升高独立相关,用药者赫尔辛基CT评分更高。

要点

  • 3031例中128例(4%)用抗血小板药,342例(11%)用抗凝药,氯吡格雷2%、华法林9%最常见。
  • 用药者中位年龄70岁 vs 未用药者52岁(p<0.001),赫尔辛基CT评分中位3 vs 2(p<0.05)。
  • 多变量分析示抗血小板药OR 1.62(95%CI 1.02-2.58)、抗凝药OR 1.43(95%CI 1.06-1.94)与1年死亡率升高独立相关。

核心结论

  • TBI前使用抗血小板药或抗凝药在本研究中是1年死亡率的危险因素。
  • 抗血小板药与抗凝药使用者的赫尔辛基CT评分定义的颅内损伤负担高于未使用者。
  • 作者认为应进一步研究DOAC对ICU治疗TBI患者死亡率的影响。

研究设计与样本

  • 回顾性、多中心观察研究,使用芬兰重症监护联盟数据库。
  • 纳入2003至2013年四所大学医院ICU收治的成人TBI患者,随访至2016年底。
  • 处方药物信息来自国家药品报销数据库,采用多变量logistic回归模型分析。

主要发现

  • 3031例患者中128例(4%)TBI前使用抗血小板药,342例(11%)使用抗凝药。
  • 最常见抗血小板药为氯吡格雷(2%),最常见抗凝药为华法林(9%),3例使用DOAC。
  • 用药者中位年龄70岁 vs 未用药者52岁(p<0.001)。
  • 用药者赫尔辛基CT评分中位3 vs 未用药者2(p<0.05)。
  • 多变量分析:抗血小板药OR 1.62(95%CI 1.02-2.58),抗凝药OR 1.43(95%CI 1.06-1.94),均与1年死亡率升高独立相关。

关键数值与推荐

  • 仅纳入70岁以上患者的敏感性分析中,抗血小板药OR 2.28(95%CI 1.16-4.22),抗凝药OR 1.50(95%CI 0.97-2.32)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Antiplatelet and anticoagulant medication are increasingly common and can increase the risks of morbidity and mortality in traumatic brain injury (TBI) patients. Our study aimed to quantify the association of antiplatelet or anticoagulant use in intensive care unit (ICU)-treated TBI patients with 1-year mortality and head CT findings. METHOD: We conducted a retrospective, multicenter observational study using the Finnish Intensive Care Consortium database. We included adult TBI patients admitted to four university hospital ICUs during 2003-2013. The patients were followed up until the end of 2016. The national drug reimbursement database provided information on prescribed medication for our study. We used multivariable logistic regression models to assess the association between TBI severity, prescribed antiplatelet and anticoagulant medication, and their association with 1-year mortality. RESULTS: Of 3031 patients, 128 (4%) had antiplatelet and 342 (11%) anticoagulant medication before their TBI. Clopidogrel (2%) and warfarin (9%) were the most common antiplatelets and anticoagulants. Three patients had direct oral anticoagulant (DOAC) medication. The median age was higher among antiplatelet/anticoagulant users than in non-users (70 years vs. 52 years, p < 0.001), and their head CT findings were more severe (median Helsinki CT score 3 vs. 2, p < 0.05). In multivariable analysis, antiplatelets (OR 1.62, 95% CI 1.02-2.58) and anticoagulants (OR 1.43, 95% CI 1.06-1.94) were independently associated with higher odds of 1-year mortality. In a sensitivity analysis including only patients over 70, antiplatelets (OR 2.28, 95% CI 1.16-4.22) and anticoagulants (1.50, 95% CI 0.97-2.32) were associated with an increased risk of 1-year mortality. CONCLUSIONS: Both antiplatelet and anticoagulant use before TBI were risk factors in our study for 1-year mortality. Antiplatelet and anticoagulation medication users had a higher radiological intracranial injury burden than non-users defined by the Helsinki CT score. Further investigation on the effect of DOACs on mortality should be done in ICU-treated TBI patients.

来源:Acta Neurochir (Wien),查看原文。版权归原作者所有。

引用

  1. Vehviläinen J, Virta JJ, Skrifvars MB, et al. Effect of antiplatelet and anticoagulant medication use on injury severity and mortality in patients with traumatic brain injury treated in the intensive care unit. Acta Neurochir (Wien). 2023. PMID: 37910309. doi:10.1007/s00701-023-05850-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。